gastrointestin
microbiota
extrem
import
human
anim
health
investig
composit
microbiota
therapeut
modif
receiv
increas
interest
human
veterinari
medicin
probiot
way
modifi
microbiota
test
prevent
treat
diseas
probiot
propos
exert
benefici
effect
variou
pathway
product
antimicrobi
compound
target
intestin
pathogen
gener
immun
stimul
colon
resist
among
mechan
despit
widespread
avail
use
scientif
peerreview
evid
behind
commerci
probiot
formul
hors
limit
addit
qualiti
control
commerci
overthecount
product
tightli
regul
although
promis
vitro
result
achiev
vivo
health
benefit
difficult
prove
whether
ambigu
result
caus
strain
select
dosag
select
true
lack
efficaci
remain
answer
although
limit
exist
probiot
increasingli
use
lack
sever
advers
effect
eas
administr
low
cost
review
summar
current
evid
probiot
use
equin
medicin
aim
provid
veterinarian
evidencebas
inform
probiot
indic
prevent
treatment
gastrointestin
diseas
hors
review
also
outlin
current
state
knowledg
equin
microbiota
potenti
fecal
microbi
transplant
relat
topic
probiot
concept
human
microbiota
first
introduc
scientif
commun
joshua
lederberg
defin
microbiota
ecolog
commun
commens
symbiot
pathogen
microorgan
liter
share
bodi
space
ignor
determin
health
diseas
sinc
interest
intestin
microbiota
culmin
largescal
endeavor
human
microbiota
project
also
made
way
veterinari
medicin
hors
colon
cecum
larg
ferment
chamber
inhabit
divers
microbiota
consist
bacteria
protozoa
fungi
intestin
microbiota
enorm
impact
health
perform
hors
although
singl
pathogen
caus
diseas
gut
microbiota
dysbiosi
shift
microbiota
whole
increasingli
identifi
caus
wide
rang
diseas
human
speci
variou
gastrointestin
diseas
inflammatori
bowel
diseas
diabet
atherosclerosi
rheumatoid
arthriti
associ
gut
dysbiosi
alter
equin
intestin
microbiota
associ
acut
coliti
equin
grass
sick
lamin
last
decad
studi
focus
hind
gut
ferment
process
relat
fiber
digest
lactic
acidosi
lamin
conduct
use
culturedepend
molecular
method
thorough
understand
composit
equin
microbiota
could
reach
technic
limit
method
recent
advanc
cultur
independ
microbi
identif
bioinformat
open
door
toward
understand
composit
intestin
microbiota
inform
obtain
studi
far
base
small
number
statist
limit
differ
analys
data
microbiota
uniqu
hors
certain
phyla
predomin
healthi
anim
firmicut
predomin
phylum
fece
account
identifi
sequenc
bacteroidet
proteobacteria
verrucomicrobia
actinobacteria
spirochaet
constitut
substanti
shift
phylum
level
occur
hors
gastrointestin
diseas
healthi
hors
greater
abund
actinobacteria
spirochet
wherea
diarrheic
hors
greater
abund
fusobacteria
also
rel
greater
abund
order
clostridial
healthi
hors
compar
diseas
hors
suggest
import
health
equin
gastrointestin
tract
interestingli
differ
rel
abund
lactobacillal
healthi
diseas
hors
order
lactobacillal
contain
major
lactic
acidproduc
bacteria
lab
commonli
use
probiot
despit
data
gut
microbiota
remain
difficult
interpret
complex
difficulti
differenti
caus
effect
poor
understand
function
differ
compon
microbiota
problem
assess
interact
microbiota
hors
detail
review
composit
equin
microbiota
health
diseas
beyond
scope
articl
found
elsewher
microbi
composit
function
known
chang
along
gastrointestin
tract
chang
domin
phyla
account
major
differ
one
studi
domin
phyla
larg
intestin
firmicut
bacteriodet
wherea
ileum
firmicut
proteobacteria
domin
core
microbiota
differ
region
differ
composit
also
abund
clinic
case
research
set
fecal
sampl
mostli
obtain
biolog
relev
differ
like
exist
among
compart
gastrointestin
tract
complic
research
interpret
clinic
applic
treatment
modal
prebiot
probiot
antimicrobi
fecal
microbi
transfaun
fmt
explor
manipul
microbiota
composit
goal
ultim
achiev
diseas
reduct
elimin
prevent
treatment
option
hold
remark
promis
investig
still
infanc
better
understand
equin
intestin
microbiota
reach
approach
modifi
microbiota
could
becom
therapeut
procedur
equin
diseas
metchnikoff
first
defin
probiot
live
microorgan
exhibit
health
promot
effect
food
agricultur
organ
fao
world
health
organ
modifi
definit
current
form
live
microorgan
administ
oral
adequ
concentr
provid
benefici
effect
beyond
nutrit
valu
unit
state
probiot
also
call
direct
fed
microbi
classifi
drug
case
need
approv
food
drug
author
fda
current
approv
probiot
hors
altern
probiot
classifi
dietari
feed
supplement
gener
regard
safe
gra
latter
case
need
go
process
drug
approv
produc
respons
provid
expert
opinion
product
consid
gra
center
veterinari
medicin
cvm
fda
approv
reject
statu
www
fdagovcom
although
fda
regulatori
respons
ultim
respons
lie
manufactur
compani
fda
requir
supplement
label
truth
mislead
manner
label
need
review
cvm
market
label
need
contain
inform
identifi
feed
addit
detail
safe
effect
use
express
impli
claim
feed
addit
use
cure
treat
prevent
diseas
may
identifi
intent
offer
product
anim
drug
allow
howev
cvm
permit
use
meaning
health
inform
label
anim
feed
product
exampl
gastrointestin
health
claim
hors
feed
fall
polici
wwwfdagovcom
consequ
north
america
numer
probiot
product
use
hors
market
obtain
counter
claim
benefit
hors
variou
way
howev
peerreview
publish
studi
prove
efficaci
product
limit
case
lack
european
union
probiot
consid
feed
addit
classifi
regulatori
level
zootechn
addit
categori
gut
flora
stabil
healthi
anim
probiot
compli
regul
ec
may
place
market
author
grant
specif
anim
speci
specif
condit
use
period
current
commerci
product
approv
use
hors
european
union
wwwefsaeuropeeu
biosprint
levucel
yeasacc
contain
saccharomyc
cerevisia
regist
claim
improv
fiber
digest
colicur
contain
escherichia
coli
licens
claim
improv
fecal
consist
odor
studi
outlin
efficaci
product
publish
peerreview
journal
although
efsa
judg
evid
adequ
licens
publish
evid
data
review
weak
mani
import
factor
choos
microorgan
develop
probiot
recent
faowho
guidelin
state
potenti
probiot
strain
abl
surviv
gastric
environ
antimicrobi
properti
adher
mucu
epitheli
cell
properti
abl
withstand
rigor
product
lab
probiot
properti
even
differ
strain
speci
differ
properti
make
necessari
evalu
probiot
strain
basi
bacteria
yeast
use
microbi
feed
addit
tabl
bacteria
compris
commerci
probiot
constitut
intestin
microorgan
total
depend
speci
segment
gastrointestin
tract
evalu
rel
abund
much
higher
mani
probiot
hors
design
target
larg
colon
hors
mani
diseas
occur
commonli
use
genera
probiot
lactobacillu
bifidobacterium
enterococci
abund
speci
larg
colon
hors
observ
suggest
speci
less
influenc
gastrointestin
health
hors
approach
use
lactobacilli
lab
probiot
mainli
use
human
small
anim
might
futil
hors
focu
probiot
studi
place
abund
speci
studi
investig
effect
abund
bacteri
speci
member
clostridia
class
lack
date
class
could
theoret
better
effect
current
probiot
strain
debat
whether
strain
isol
target
host
better
surviv
colon
capabl
host
specif
lactobacillu
speci
healthi
equin
fece
gastric
epithelium
highli
adher
cell
equin
digest
tract
hand
enterococci
probiot
properti
isol
healthi
hors
fece
shown
adher
best
human
canin
mucu
phenomenon
seen
lab
isol
human
dog
thu
appear
abil
probiot
colon
intestin
tract
alway
hostspecif
indic
strain
chosen
base
probiot
properti
origin
technic
instabl
bacteri
strain
import
commerci
product
often
limit
factor
evalu
strain
alreadi
commerci
product
limit
overcom
antibiot
resist
import
select
criterion
bacteri
strain
intend
use
probiot
transferr
resist
gene
present
probiot
bacteria
chromosom
plasmid
may
transfer
horizont
indigen
flora
opportunist
pathogen
bacteria
thu
ideal
probiot
harbor
potenti
transfer
resist
gene
especi
confer
resist
trait
high
clinic
relev
probiot
strain
member
human
anim
indigen
flora
presenc
antibiot
resist
determin
must
system
evalu
europ
probiot
market
undergo
evalu
resist
gene
content
consid
qp
standard
follow
potenti
market
product
wwwefsaeuropeeu
north
america
regul
current
forc
possibl
resist
transfer
relat
genet
basi
resist
mechan
horizont
transfer
antibiot
resist
gene
particularli
carri
within
mobil
genet
element
like
transmit
differenti
antibiot
resist
mechan
involv
therefor
extrem
import
enterococci
often
carri
mobil
genet
element
contain
multipl
resist
gene
code
resist
clinic
relev
antibiot
exampl
enterococci
isol
aquat
cultur
display
acquir
antibiot
resist
penicillin
nineteen
percent
isol
resist
vancomycin
e
faecium
strain
multidrug
resist
antibiot
creat
potenti
concern
common
use
enterococci
probiot
limit
data
regard
suscept
enterococci
probiot
product
data
antibiot
resist
determin
mostli
avail
lactobacilli
scarc
bacteri
speci
common
resist
gene
code
tetracyclin
resist
chloramphenicol
macrolid
aminoglycosid
betalactam
resist
gene
also
identifi
transfer
gene
shown
occur
vitro
anim
model
among
lactobacillu
strain
lactobacilli
differ
gramposit
bacteria
includ
staphylococci
lactobacilli
also
acquir
resist
gene
gramposit
bacteria
taken
togeth
result
support
hypothesi
probiot
act
antibiot
resist
traffick
vivo
situat
colon
superior
mere
surviv
gastrointestin
tract
probiot
could
act
beyond
period
administr
gener
hostspecif
strain
believ
abl
colon
gastrointestin
tract
indigen
host
longer
period
time
inde
colon
adult
equin
gastrointestin
tract
l
rhamnosu
lgg
human
origin
shown
poor
cours
probiot
administr
differ
dosag
fecal
recoveri
adult
shown
h
dose
respect
h
probiot
recov
fece
wherea
day
administr
hors
lower
dosag
group
remain
posit
fecal
recoveri
longer
foal
probiot
could
recov
day
administr
foal
suggest
immatur
gastrointestin
flora
foal
could
facilit
probiot
surviv
addit
foal
adult
show
lack
dose
respons
make
difficult
determin
ideal
dose
use
similar
result
obtain
administ
saccharomyc
boulardii
administr
cfug
hors
cfug
hors
day
fecal
sampl
neg
boulardii
day
day
hors
viabl
boulardii
fece
similarli
cerevisia
shown
surviv
colon
ceca
colon
hors
indic
benefici
effect
probiot
might
continu
beyond
period
administr
make
longterm
repeat
treatment
necess
studi
probiot
surviv
assess
analys
fecal
sampl
approach
colon
detect
anim
shed
bacterium
time
sampl
whether
certain
bacteria
shed
persist
intermitt
hors
mani
sampl
requir
detect
intermitt
shed
histor
topic
great
debat
number
fecal
sampl
necessari
establish
salmonella
shed
exampl
conclus
determin
far
like
depend
preval
bacterium
probiot
bacteria
current
inform
intermitt
persist
shed
avail
literatur
main
mechan
action
probiot
prevent
colon
digest
tract
pathogen
strain
prevent
diseas
modul
host
innat
acquir
immun
system
antimicrobi
product
competit
exclus
inhibit
inactiv
bacteri
toxin
fig
b
mani
report
mechan
action
probiot
base
vitro
studi
extrapol
result
vivo
condit
controversi
evid
also
gener
vivo
studi
done
laboratori
anim
human
probiot
influenc
host
immun
system
live
dead
bacteria
metabolit
cell
wall
compon
dna
probiot
metabol
product
recogn
conserv
recognit
receptor
iec
gutassoci
immun
cell
effect
includ
fortif
intestin
barrier
maintain
tight
junction
support
surviv
intestin
epitheli
cell
iec
growth
induct
iga
bdefensin
product
result
suppress
growth
pathogen
well
system
local
antiinflammatori
effect
antiinflammatori
effect
achiev
modif
cytokin
product
iec
effect
cell
innat
immun
system
macrophag
dendrit
cell
probiot
product
influenc
reg
cell
subset
tcell
play
import
role
downregul
misdirect
immun
respons
probiot
abl
induc
product
reg
cell
therebi
exert
antiinflammatori
properti
although
probiot
often
exert
antiinflammatori
action
certain
probiot
bacteria
also
upregul
inflammatori
mediat
product
increas
adhes
pathogen
within
intestin
wall
bcell
differenti
plasma
cell
secret
iga
antibodi
transport
lumen
import
mucosalassoci
immun
certain
probiot
strain
abl
influenc
iga
product
system
probiot
influenc
immunoglobulin
product
alter
system
isotyp
profil
probiot
divers
effect
immun
system
effect
stimulatori
inhibitori
depend
biolog
featur
individu
probiot
strain
studi
assess
effect
probiot
host
conduct
use
human
laboratori
anim
cell
line
equival
studi
lack
hors
given
conserv
immun
system
across
speci
like
similar
effect
would
occur
hors
probiot
strain
produc
variou
substanc
effect
microb
fatti
acid
lactic
acid
acet
acid
produc
larg
quantiti
addit
antimicrobi
substanc
produc
much
smaller
amount
lab
includ
formic
acid
free
fatti
acid
ammonia
hydrogen
peroxid
diacetyl
bacteriolyt
enzym
bacteriocin
antibiot
sever
undefin
substanc
probiot
strain
adher
epitheli
cell
host
interfer
pathogen
adher
block
receptor
increas
mucin
product
l
rhamnosu
gg
decreas
adher
pathogen
bacteria
salmonella
e
coli
clostridia
pig
intestin
mucu
mechan
howev
appear
specif
certain
probiot
strain
strain
increas
adher
pathogen
bacteria
human
intestin
mucu
vitro
probiot
prevent
pathogen
bacteria
invad
epitheli
cell
contrast
former
describ
effect
featur
seem
widespread
trait
among
probiot
bacteria
toxin
import
virul
factor
enteropathogen
bacteria
probiot
block
effect
enteropathogen
bacteria
exampl
boulardii
protect
murin
ileal
loop
model
well
cell
cytotox
assay
challeng
toxigen
c
difficil
mechan
lactobacilli
decreas
toxin
gene
express
toxin
product
bacteria
includ
salmonella
e
coli
c
perfringen
antitoxin
effect
probiot
may
benefici
manag
infecti
diarrhea
fig
mechan
action
probiot
modifi
thoma
versalov
probiot
alter
pain
percept
gastrointestin
motil
interact
enter
nervou
system
interact
probiot
dendrit
cell
wall
intestin
modul
tcell
respons
turn
influenc
differenti
bcell
immunoglobulin
product
probiot
also
modul
cytokin
product
well
prolifer
surviv
macrophag
probiot
increas
bdefensin
product
intestin
epitheli
cell
enhanc
mucin
product
contribut
colon
resist
probiot
substanc
produc
direct
effect
pathogen
toxin
b
probiot
also
abl
inactiv
toxin
metabol
mechan
saccharomyc
boulardii
releas
proteas
digest
c
difficil
toxin
potenti
prevent
c
difficil
infect
inactiv
also
occur
physicochem
interact
probiot
bind
toxin
decreas
bioavail
host
qualiti
control
commerci
product
describ
earlier
manufactur
overthecount
product
north
america
oblig
perform
qualiti
control
product
europ
licens
product
period
test
efsa
wwwefsacom
effect
probiot
might
therefor
predict
inadequ
content
commerci
probiot
formul
mani
commerci
veterinari
human
probiot
prepar
accur
repres
label
claim
fig
human
product
veterinari
product
canada
adequ
label
three
human
veterinari
product
contain
inadequ
descript
bacteri
content
includ
miss
name
unspecifi
strain
nonexist
name
outdat
name
human
veterinari
product
canada
provid
inform
bacteri
concentr
qualiti
control
content
also
poor
veterinari
human
probiot
contain
specifi
organ
label
indic
concentr
product
miss
organ
entir
contain
littl
much
activ
ingredi
actual
bacteri
concentr
rang
claim
amount
veterinari
product
contain
list
concentr
adequ
label
defin
contain
specif
valid
name
bacteria
spell
mistak
expect
bacteri
content
product
label
correctli
list
bacteri
speci
misspel
product
disclos
expect
amount
activ
ingredi
bacteria
label
met
exceed
claim
amount
research
studi
affect
poor
qualiti
control
part
clinic
trial
content
commerci
probiot
formul
evalu
although
formul
claim
contain
million
viabl
lactobacilli
cfug
cfug
cultur
posit
effect
probiot
seen
studi
uncertain
whether
true
lack
effect
probiot
whether
probiot
contain
adequ
number
clinic
effect
advers
effect
probiot
administr
rare
human
anim
human
report
avail
usual
describ
extraintestin
infect
enter
diseas
although
probiot
typic
use
individu
enter
diseas
advers
enter
consequ
might
hard
discern
reason
assum
incid
advers
event
low
someth
consist
gra
classif
adult
hors
publish
report
enter
diseas
probiot
administr
dose
gener
extrapol
human
recommend
adjust
weight
even
administr
time
manufactur
recommend
dose
healthi
hors
result
advers
effect
effect
probiot
hors
enter
diseas
might
differ
effect
healthi
hors
advers
clinic
effect
report
hors
gastrointestin
diseas
base
data
author
consid
probiot
particularli
boulardii
safe
use
healthi
diseas
adult
hors
advers
effect
relat
enter
diseas
report
one
hors
develop
hive
administr
probiot
associ
hive
probiot
unclear
resolut
hive
coincid
hors
switch
straw
bed
wood
shave
indic
bed
could
reason
allerg
reaction
effect
probiot
foal
like
differ
adult
hors
major
differ
gastrointestin
microbiota
composit
although
sever
publish
studi
demonstr
safeti
commerci
avail
selfmad
probiot
foal
also
report
advers
enter
effect
selfmad
probiot
product
contain
lactobacillu
pentosu
isol
healthi
foal
evalu
abil
prevent
neonat
diarrhea
preliminari
studi
probiot
administ
healthi
foal
advers
effect
seen
probiot
administ
healthi
neonat
clinic
placebocontrol
field
trial
treatment
group
show
increas
incid
diarrhea
need
veterinari
intervent
although
unclear
foal
develop
diarrhea
immatur
microbiota
foal
could
allow
overgrowth
lab
result
osmot
imbal
diarrhea
altern
probiot
could
chang
microbiota
allow
pathogen
adhes
epitheli
cell
fungaemia
caus
treatment
boulardii
report
neonat
human
whether
could
problem
hors
unknown
studi
hors
far
exclud
neonat
studi
boulardii
scope
current
literatur
equin
probiot
use
focus
mainli
gastrointestin
diseas
applic
fig
although
studi
shown
benefici
effect
probiot
studi
could
corrobor
result
overal
studi
avail
compar
easili
differ
studi
design
formul
use
consequ
overal
evid
weak
follow
section
summar
variou
clinic
applic
probiot
test
exact
strain
dosag
length
treatment
use
studi
cite
text
outlin
tabl
acut
coliti
potenti
devast
disord
caus
sever
pathogen
treatment
mainli
support
etiolog
agent
identifi
case
increas
interest
find
adjunct
treatment
modal
saccharomyc
boulardii
assess
random
blind
placebocontrol
clinic
trial
hors
receiv
boulardii
shorter
durat
diarrhea
wateri
diarrhea
loos
fece
despit
posit
effect
result
studi
must
interpret
caution
differ
group
relat
outcom
durat
hospit
recurr
diarrhea
addit
confound
factor
addit
treatment
number
case
low
hors
per
group
saccharomyc
boulardii
also
assess
adjunct
treatment
hors
affect
antimicrobialassoci
enterocol
random
placebocontrol
clinic
trial
involv
hors
signific
differ
observ
group
occurr
normal
fecal
consist
cessat
wateri
diarrhea
also
day
improv
attitud
resolut
leukopenia
appetit
normal
heart
rate
normal
respiratori
rate
normal
temperatur
durat
stay
hospit
surviv
discharg
occurr
secondari
complic
differ
group
author
postul
lack
efficaci
could
attribut
lack
colon
boulardii
fecal
sampl
hors
neg
boulardii
although
studi
influenc
fewer
confound
factor
evalu
clinic
paramet
compar
previous
describ
studi
number
case
low
adjunct
treatment
variabl
among
hors
make
interpret
result
difficult
although
studi
investig
probiot
agent
difficult
compar
heterogen
hors
popul
differ
inclus
outcom
criteria
overal
evid
effect
boulardii
adjunct
treatment
enterocol
hors
weak
given
drastic
chang
microbiota
hors
enterocol
identifi
question
whether
administr
current
avail
probiot
contain
limit
number
bacteri
strain
could
effect
neonat
foal
diarrhea
common
occurr
foal
develop
diarrhea
first
week
life
etiolog
numer
prevent
measur
limit
probiot
administr
attract
option
prevent
neonat
foal
diarrhea
studi
equin
strain
lactobacillu
pentosu
vitro
antimicrobi
properti
assess
random
placebocontrol
clinic
trial
probiot
administr
studi
associ
significantli
higher
incid
diarrhea
presenc
clinic
sign
lethargi
fever
anorexia
colic
need
veterinari
examin
treatment
anoth
studi
multistrain
probiot
product
deriv
equin
gastrointestin
content
studi
random
placebocontrol
doubleblind
clinic
trial
foal
probiot
group
show
statist
signific
larger
weight
gain
treatment
significantli
lower
incid
diarrhea
effect
howev
signific
time
point
week
age
unlik
diarrhea
clinic
import
evidenc
lack
differ
need
medic
intervent
group
studi
compar
directli
differ
product
use
howev
result
show
probiot
product
must
evalu
separ
assess
safeti
efficaci
neonat
foal
larger
scale
control
studi
differ
strain
product
necessari
conclus
drawn
clinic
efficaci
probiot
specif
applic
probiot
use
success
control
infect
salmonella
spp
poultri
calv
hors
effect
probiot
salmonella
shed
investig
studi
result
disappoint
date
doubleblind
random
placebocontrol
trial
effect
commerci
multistrain
probiot
formul
tabl
fecal
shed
salmonella
studi
postop
period
colic
surgeri
total
hors
prospect
alloc
treatment
group
probiot
placebo
treat
consecut
day
daili
five
cluster
gastrointestin
diseas
evenli
distribut
treatment
group
differ
salmonella
shed
rate
found
treatment
group
overal
shed
rate
preval
postop
diarrhea
durat
antimicrobi
therapi
durat
hospit
statist
differ
group
later
placebocontrol
random
trial
effect
multistrain
commerci
probiot
tabl
salmonella
shed
preval
diarrhea
leukopenia
fever
evalu
colic
case
variou
underli
diseas
ninetysix
hors
enrol
receiv
probiot
placebo
daili
day
overal
shed
rate
salmonella
differ
observ
shed
rate
clinic
paramet
probioticand
placebotr
group
despit
success
random
studi
limit
overal
number
hors
shed
salmonella
small
n
number
hors
develop
diarrhea
fever
leukopenia
report
neither
antimicrobi
administr
limit
could
greatli
influenc
multivari
analysi
perform
studi
addit
fecal
sampl
taken
irregular
arbitrari
interv
given
salmonella
shed
intermitt
case
might
miss
addit
studi
use
commerci
product
test
assess
actual
content
claim
label
prevent
effect
multistrain
commerci
probiot
tabl
salmonella
shed
hospit
hors
without
gastrointestin
diseas
assess
random
placebocontrol
doubleblind
clinic
trial
involv
hors
hors
given
probiot
placebo
admiss
medic
procedur
commenc
pretreat
differ
group
although
administr
probiot
decreas
incid
salmonella
shed
result
signific
p
posthoc
analysi
show
studi
power
show
differ
addit
incid
number
low
case
detect
placebo
probiot
group
respect
throughout
studi
speci
known
effect
probiot
depend
agent
studi
far
probiot
evalu
hors
addit
studi
necessari
exclud
benefici
effect
probiot
salmonella
shed
hors
current
littl
evid
support
use
probiot
decreas
salmonella
shed
salmonellosi
hors
probiot
product
colicur
contain
e
coli
licens
efsa
improv
fecal
consist
publish
studi
peerreview
scientif
literatur
product
inform
avail
efficaci
obtain
efsa
scientif
opinion
wwwefsacom
studi
submit
manufactur
fecal
consist
improv
treat
anim
scale
studi
contain
control
popul
fecal
consist
improv
control
anim
well
albeit
slower
rate
inclus
criteria
case
determin
provid
inform
start
point
poor
fecal
consist
well
endpoint
improv
defin
subject
studi
healthi
hors
abnorm
hors
microbiolog
analysi
perform
increas
number
coliform
decreas
number
clostridium
bacillu
spp
treat
hors
note
although
would
indic
effect
probiot
microbiota
hors
reason
describ
cultur
inher
technic
limit
assess
microbiota
unclear
whether
chang
note
actual
repres
benefici
effect
intestin
microbiota
particularli
true
given
recent
studi
indic
clostridia
import
compon
intestin
microbiota
decreas
group
actual
may
desir
effect
combin
probiot
prebiot
psyllium
product
fecal
sand
clearanc
natur
set
evalu
eight
adult
healthi
equid
hors
mule
includ
trial
anim
serv
control
baselin
sand
excret
measur
day
anim
receiv
preprobiot
mixtur
daili
day
fecal
sand
clearanc
measur
fecal
sand
output
increas
significantli
day
start
treatment
remain
time
higher
averag
throughout
treatment
period
whether
effect
caus
psyllium
probiot
combin
thereof
determin
studi
sever
clinic
case
report
describ
efficaci
prebiot
hors
publish
littl
clinic
evid
substanti
claim
feed
psyllium
help
prevent
treat
sand
accumul
gastrointestin
microbiota
human
anim
consist
thousand
microbi
speci
interact
probiot
gastrointestin
microbiota
investig
document
mani
studi
exist
probiot
consist
strain
compromis
minor
compon
intestin
microbiota
therefor
might
limit
abil
influenc
individu
entir
gastrointestin
microbiota
mind
scientist
look
end
probiot
complex
spectrum
fecal
transplant
fecal
transplant
consist
intact
highli
complex
microbi
commun
compos
thousand
speci
fecal
microbi
transplant
fmt
constitut
transfer
fecal
suspens
healthi
donor
bowel
recipi
prior
antimicrobi
administr
decreas
resid
microbiota
colonoscopi
retent
enema
nasogastr
tube
nasoduoden
tube
attempt
fecal
microbi
transplant
novel
therapeut
modal
first
report
human
medicin
date
back
sixteenth
centuri
howev
recent
receiv
increas
attent
sever
publish
studi
show
fece
biolog
activ
mixtur
live
organ
great
potenti
treatment
c
difficil
infect
gastrointestin
nongastrointestin
disord
human
medicin
applic
fmt
recurr
c
difficil
infect
current
best
research
two
systemat
review
show
form
therapi
safe
effect
patient
achiev
sustain
full
resolut
clinic
sign
recent
fmt
also
emerg
veterinari
medicin
peerreview
publish
studi
use
fmt
domest
anim
ongo
clinic
trial
fecal
transplant
use
treat
dog
cat
inflammatori
bowel
diseas
far
enrol
cat
dog
treat
success
transfer
healthi
donor
fece
colonoscopi
recipi
although
publish
studi
abstract
hors
anecdot
report
suggest
form
therapi
also
might
effect
hors
acut
coliti
chronic
diarrhea
probiot
strain
limit
abil
colon
gastrointestin
tract
long
period
time
fecal
transplant
might
last
effect
colon
fecal
microbi
transplant
studi
human
shown
index
bacteria
still
present
fece
patient
week
treatment
indic
perman
chang
microbiota
associ
resolut
clinic
sign
safeti
fmt
rare
investig
minor
advers
effect
observ
sporad
systemat
review
approxim
patient
treat
fmt
recurr
c
difficileassoci
diarrhea
screen
potenti
fmt
donor
occurr
pathogen
organ
major
point
discuss
ideal
type
number
pathogen
speci
screen
speci
depend
hors
screen
presenc
salmonella
c
difficil
equin
infecti
anemia
viru
recommend
whether
infecti
agent
coronaviru
rotaviru
includ
screen
need
evalu
gener
agre
prior
antibiot
treatment
exclud
hors
donor
howev
durat
time
sinc
last
antibiot
administr
elaps
remain
specul
although
probiot
shown
promis
treatment
select
diseas
human
evid
use
control
diseas
hors
far
weak
aim
develop
probiot
aid
prevent
treatment
diseas
unrealist
bacteri
strain
differ
effect
choic
combin
strain
therapeut
formul
need
specif
diseas
base
vitro
properti
strain
random
placebocontrol
clinic
trial
control
condit
necessari
provid
evid
probiot
formul
hors
base
lack
regul
regard
qualiti
control
commerci
product
use
overthecount
product
question
particularli
absenc
scientif
inform
safeti
clinic
efficaci
efficaci
trial
conduct
publish
peerreview
journal
recommend
use
product
also
care
evalu
composit
concentr
investig
clinic
trial
ensur
efficaci
reproduc
result
despit
limit
probiot
gener
regard
safe
cost
effect
easi
administ
therefor
addit
research
warrant
test
possibl
applic
equin
veterinari
practic
exploit
new
knowledg
composit
equin
microbiota
focu
probiot
research
shift
current
use
agent
speci
abund
intestin
microbiota
hors
particular
emphasi
given
bacteri
speci
associ
microbiota
healthi
hors
approach
administ
strain
togeth
rethought
background
vast
microbiota
given
promis
result
fmt
human
clinic
efficaci
approach
test
prevent
treatment
enterocol
hors
